Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) EBIT : $-63.18 Mil (TTM As of Mar. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Checkmate Pharmaceuticals EBIT?

Checkmate Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2022 was $-15.89 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2022 was $-63.18 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Checkmate Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2022 was -1,308.84%. Checkmate Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2022 was -8,405.29%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Checkmate Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2022 was -36.87%.

Checkmate Pharmaceuticals EBIT Historical Data

The historical data trend for Checkmate Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkmate Pharmaceuticals EBIT Chart

Checkmate Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

EBIT

-20.99

-28.89

-36.90

-61.47

Checkmate Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
EBIT	Get a 7-Day Free Trial									-14.18	-18.96	-14.98	-13.35	-15.89

Competitive Comparison of Checkmate Pharmaceuticals's EBIT

For the Biotechnology subindustry, Checkmate Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Checkmate Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Checkmate Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Checkmate Pharmaceuticals's EV-to-EBIT falls into.

Checkmate Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-63.18 Mil.

Checkmate Pharmaceuticals (NAS:CMPI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Checkmate Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2022 is calculated as:

	ROC % (Q: Mar. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2021 )	+	Invested Capital (Q: Mar. 2022 ))	/ count )
=	-63.544 * ( 1 - 0% )	/	( (4.876	+	4.834)	/ 2 )
=	-63.544	/	4.855
=	-1,308.84 %

where

	Invested Capital		(Q: Dec. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	78.838	-	9.379	-	( 70.867	-	max(0, 9.379	-	73.962	+	70.867	))
=	4.876

	Invested Capital		(Q: Mar. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	66.944	-	11.942	-	( 60.033	-	max(0, 11.942	-	62.11	+	60.033	))
=	4.834

Note: The Operating Income data used here is four times the quarterly (Mar. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Checkmate Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2021		Q: Mar. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-63.544	/	( ( (0.777 + max(-6.284, 0))	+	(0.735 + max(-9.865, 0)) )	/	2 )
=	-63.544	/	( ( 0.777	+	0.735 )	/	2 )
=	-63.544	/	0.756
=	-8,405.29 %

where Working Capital is:

	Working Capital		(Q: Dec. 2021 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	3.095)	-	(9.379	+	0	+	0)
=	-6.284

	Working Capital		(Q: Mar. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.077)	-	(11.942	+	0	+	0)
=	-9.865

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Checkmate Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2022 )
	=	-63.175	/	171.368
	=	-36.87 %

Checkmate Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of Checkmate Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkmate Pharmaceuticals Inc (NAS:CMPI) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142

Website

https://www.checkmatepharma.com

Checkmate Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing its proprietary technology to harness the power of the immune system to combat cancer.

Executives

Venbio Global Strategic Fund Ii L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Alan Bash	director, officer: Chief Executive Officer	C/O CHECKMATE PAHRMACEUTICALS, INC. 245 MAIN STREET 2ND FLOOR CAMBRIDGE MA 02142
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Jon Marc Wigginton	director	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Joy Yan	director	10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Arthur M Krieg	director, officer: Chief Scientific Officer	C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Robert Dolski	officer: Chief Financial Officer	C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Barry Labinger	director, officer: President and CEO	C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Peter Colabuono	director	C/O DECHENG CAPITAL 3000 SAND HILL ROAD, BUILDING 2, STE 110 MENLO PARK CA 94025
Oren Isacoff	director	C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025
Karen Brennan	officer: Chief Operating Officer	C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Kleem Chaudhary	officer: Chief Business Officer	C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Venbio Global Strategic Gp Ii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Gp Ii, Ltd.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Nilesh Kumar	director	C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6